352 related articles for article (PubMed ID: 26205912)
1. Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.
Sheehy KA; Finkel JC; Darbari DS; Guerrera MF; Quezado ZM
Pain Pract; 2015 Nov; 15(8):E90-7. PubMed ID: 26205912
[TBL] [Abstract][Full Text] [Related]
2. Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.
Calhoun G; Wang L; Almeida LE; Kenyon N; Afsar N; Nouraie M; Finkel JC; Quezado ZM
Eur J Pharmacol; 2015 May; 754():125-33. PubMed ID: 25724786
[TBL] [Abstract][Full Text] [Related]
3. Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series.
Palm N; Floroff C; Hassig TB; Boylan A; Kanter J
J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):20-26. PubMed ID: 29791238
[TBL] [Abstract][Full Text] [Related]
4. The Use of Dexmedetomidine in Pediatric Palliative Care: A Preliminary Study.
Burns J; Jackson K; Sheehy KA; Finkel JC; Quezado ZM
J Palliat Med; 2017 Jul; 20(7):779-783. PubMed ID: 28186850
[TBL] [Abstract][Full Text] [Related]
5. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.
Nobrega R; Sheehy KA; Lippold C; Rice AL; Finkel JC; Quezado ZMN
Pediatr Res; 2018 Feb; 83(2):445-454. PubMed ID: 28902183
[TBL] [Abstract][Full Text] [Related]
6. Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Neri CM; Pestieau SR; Darbari DS
Paediatr Anaesth; 2013 Aug; 23(8):684-9. PubMed ID: 23565738
[TBL] [Abstract][Full Text] [Related]
7. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial.
Lubega FA; DeSilva MS; Munube D; Nkwine R; Tumukunde J; Agaba PK; Nabukenya MT; Bulamba F; Luggya TS
Scand J Pain; 2018 Jan; 18(1):19-27. PubMed ID: 29794277
[TBL] [Abstract][Full Text] [Related]
8. Dexmedetomidine as an adjuvant for perioperative pain management in adolescents undergoing bariatric surgery: An observational cohort study.
Vaughns JD; Martin C; Nelson J; Nadler E; Quezado ZM
J Pediatr Surg; 2017 Nov; 52(11):1787-1790. PubMed ID: 28465076
[TBL] [Abstract][Full Text] [Related]
9. Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study.
Rollé A; Vidal E; Laguette P; Garnier Y; Delta D; Martino F; Portecop P; Etienne-Julan M; Piednoir P; De Jong A; Romana M; Bernit E
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138299
[No Abstract] [Full Text] [Related]
10. An innovative intervention for the prevention of vaso-occlusive episodes in sickle cell disease.
Jeon WJ; Joung B; Moon JH; Hino C; Park D; Pham B; Castillo DR; Chong E; Kaur S; Grismore C; Cao H
Hematology; 2023 Dec; 28(1):2215575. PubMed ID: 37227254
[TBL] [Abstract][Full Text] [Related]
11. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease.
Tawfic QA; Faris AS; Kausalya R
J Pain Symptom Manage; 2014 Feb; 47(2):334-40. PubMed ID: 23856095
[TBL] [Abstract][Full Text] [Related]
12. Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises.
Hagedorn JM; Monico EC
Pediatr Emerg Care; 2019 Jan; 35(1):78-79. PubMed ID: 27902670
[TBL] [Abstract][Full Text] [Related]
13. State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.
Puri L; Nottage KA; Hankins JS; Anghelescu DL
Paediatr Drugs; 2018 Feb; 20(1):29-42. PubMed ID: 28853040
[TBL] [Abstract][Full Text] [Related]
14. Ketamine and lidocaine infusions decrease opioid consumption during vaso-occlusive crisis in adolescents with sickle cell disease.
Puri L; Morgan KJ; Anghelescu DL
Curr Opin Support Palliat Care; 2019 Dec; 13(4):402-407. PubMed ID: 31157658
[TBL] [Abstract][Full Text] [Related]
15. Opioid-free perioperative analgesia for hemicolectomy in a patient with opioid-induced delirium: a case report and review of the analgesic efficacy of the alpha-2 agonist agents.
Patil SK; Anitescu M
Pain Pract; 2012 Nov; 12(8):656-62. PubMed ID: 22448806
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of ketamine for the management of vaso-occlusive pain in sickle cell disease.
Harris EM; Vilk E; Heeney MM; Solodiuk J; Greco C; Archer NM
Pediatr Blood Cancer; 2021 Jul; 68(7):e28989. PubMed ID: 33788404
[TBL] [Abstract][Full Text] [Related]
17. Perioperative analgesic profile of dexmedetomidine infusions in morbidly obese undergoing bariatric surgery: a meta-analysis and trial sequential analysis.
Singh PM; Panwar R; Borle A; Mulier JP; Sinha A; Goudra B
Surg Obes Relat Dis; 2017 Aug; 13(8):1434-1446. PubMed ID: 28396128
[TBL] [Abstract][Full Text] [Related]
18. Tramadol infusion for the pain management in sickle cell disease: a case report.
Erhan E; Inal MT; Aydinok Y; Balkan C; Yegul I
Paediatr Anaesth; 2007 Jan; 17(1):84-6. PubMed ID: 17184440
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Small Dose Ketamine and Dexmedetomidine Infusion for Postoperative Analgesia in Spine Surgery--A Prospective Randomized Double-blind Placebo Controlled Study.
Garg N; Panda NB; Gandhi KA; Bhagat H; Batra YK; Grover VK; Chhabra R
J Neurosurg Anesthesiol; 2016 Jan; 28(1):27-31. PubMed ID: 26018671
[TBL] [Abstract][Full Text] [Related]
20. Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literature.
Uprety D; Baber A; Foy M
Ann Hematol; 2014 May; 93(5):769-71. PubMed ID: 24232306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
